Physician profile
Matt Morgan
NPI 1962403154
$11,886.13
in general payments reported to CMS, 2019-2025
34 companies · $3,064 in 2025
The $3,064 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $678 · 2021: $1,235 · 2022: $1,755 · 2023: $1,915 · 2024: $2,365 · 2025: $3,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,109 · Education: $141 · Consulting Fee: $94.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,108.70 |
| Education | $140.77 |
| Consulting Fee | $94.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,247.71 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $2,032.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,162.33 | 2019-2025 | Dupixent |
| Pfizer INC. | $869.14 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $801.13 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Csl Behring | $617.91 | 2019-2024 | Haegarda, Hizentra, Kcentra |
| Genzyme Corporation | $580.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $284.18 | 2019-2025 | |
| Optinose US, INC. | $221.15 | 2019-2025 | |
| Amgen INC. | $205.41 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $202.61 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $201.68 | 2022-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Leo Pharma INC. | $154.13 | 2022-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $148.30 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $131.86 | 2022-2025 | Ruconest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $128.53 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $125.56 | 2020-2025 | |
| Kaleo, INC. | $116.62 | 2019-2022 | |
| Adma Biomanufacturing LLC | $94.79 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $77.46 | 2019-2020 | |
| Incyte Corporation | $58.68 | 2021-2023 | Opzelura |
| Regeneron Pharmaceuticals, INC. | $56.69 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $50.00 | 2022 | |
| Merck Sharp & Dohme LLC | $49.39 | 2021-2023 | |
| Galderma Laboratories, L.P. | $46.42 | 2025 | Nemluvio |
| Tersera Therapeutics LLC | $38.56 | 2023 | Quzyttir |
| Organon LLC | $29.08 | 2025 | Vtama |
| Mylan Specialty L.P. | $27.31 | 2023 | Yupelri |
| Ars Pharmaceuticals Operations, INC. | $24.53 | 2025 | Neffy |
| Gc Biopharma USA, INC. | $24.00 | 2025 | Alyglo |
| Shire North American Group INC | $23.02 | 2019 | |
| Lilly USA, LLC | $22.36 | 2025 | Ebglyss |
| Covis Pharma Gmbh | $16.76 | 2022 | |
| Ionis Pharmaceuticals, INC. | $15.75 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matt Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.